Evaluation of high dose post-dialytic versus daily beta-lactam dosing in hemodialysis patients using Monte Carlo simulation
High-dose post-HD dosing appears feasible for ceftazidime/avibactam but may be inadequate for cefepime and meropenem over a 3-day interdialytic period. Elevated neurotoxicity risk predicted with higher cefepime doses highlights the importance of cautious dosing and consideration of therapeutic drug monitoring.
Authors
- Olivier Pauly
- Sierra Shoemaker
- Susan J. Lewis (ORCID: https://orcid.org/0000-0002-9876-2948)
- N. Wan
- S. Payer
- Adrian Bauman (ORCID: https://orcid.org/0000-0002-0369-4621)
- Olivia G. Caiazza
Institutions
- University of Findlay (US)
- Hillcrest Hospital (US)
- St. Anne Mercy Hospital (US)
- HonorHealth (US)
- South Pointe Hospital (US)
- Mercy Health (US)
Publication Details
- Journal
- International Journal of Clinical Pharmacy
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1007/s11096-025-02044-5
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 0.00